Understanding the quality of protein loaded PLGA nanoparticles variability by Plackett-Burman design

International Journal of Pharmaceutics

Volumn 389, Issue 1-2, 2010, Pages 186-194

  Rahman, Ziyaur ^a   Zidan, Ahmed S ^a,b   Habib, Muhammad J ^c   Khan, Mansoor A ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Zagazig University   (Egypt)

^c HOWARD UNIVERSITY   (United States)

Author keywords

CyA; Nanoparticles and dissolution efficiency; Plackett Burman; PLGA; QbD

Indexed keywords

CYCLOSPORIN A; NANOPARTICLE; POLYGLACTIN;

ANALYTIC METHOD; ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DESIGN; DRUG DIFFUSION; DRUG FORMULATION; DRUG SOLUBILITY; INFRARED SPECTROSCOPY; NANOENCAPSULATION; PARTICLE SIZE; PLACKETT BURMAN SCREENING EXPERIMENTAL DESIGN; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SUSTAINED DRUG RELEASE; X RAY POWDER DIFFRACTION; ZETA POTENTIAL;

CHEMISTRY, PHARMACEUTICAL; CYCLOSPORINE; DELAYED-ACTION PREPARATIONS; DIFFUSION; DRUG CARRIERS; EMULSIONS; EXCIPIENTS; IMMUNOSUPPRESSIVE AGENTS; LACTIC ACID; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID; SOLUBILITY; SOLVENTS; TIME FACTORS;

EID: 77349122289     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.12.040     Document Type: Article

References (39)

1. Akhavan A., and Rudikoff D. Atopic dermatitis: systemic immunosuppressive therapy. Semin. Cutan. Med. Surg. 27 (2008) 151-155
2. Akman-Demir G., Ayranci O., Kurtuncu M., Vanli E.N., Mutlu M., and Tugal-Tutkun I. Cyclosporine for Behçet's uveitis: is it associated with an increased risk of neurological involvement?. Clin. Exp. Rheumatol. 26 (2008) S84-S90
3. Bertacche V., Pini E., Stradi R., and Stratta F. Quantitative determination of amorphous cyclosporine in crystalline cyclosporine samples by Fourier transform infrared spectroscopy. J. Pharm. Sci. 95 (2005) 159-166
4. Carrio A., Schwach G., Coudane J., and Vert M. Preparation and degradation of surfactant-free PLGA microspheres. J. Control. Release 37 (1995) 113-121
5. Charuk J.H., Wong P.Y., and Reithmeier R.A. Differential interaction of human renal P-glycoprotein with various metabolites and analogues of cyclosporin A. Am. J. Physiol. 269 (1995) F31-F39
6. Chopra S., Patil G.V., and Motwani S.K. Release modulating hydrophilic matrix systems of losartan potassium: optimisation of formulation using statistical experimental design. Eur. J. Pharm. Biopharm. 66 (2007) 73-82
7. Costanzo A., Talamonti M., Spallone G., Botti E., Chimenti M.S., Papoutsaki M., and Chimenti S. Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy. Dermatology 218 (2009) 146-150
8. Couvreur P., Blanco-Prieto M.J., Puisieux F., Roques B., and Fattal E. Multiple emulsion technology for the design of microspheres containing peptides and oligopeptides. Adv. Drug. Deliv. Rev. 28 (1997) 85-96
9. Czogalla A. Oral cyclosporine A-the current picture of its liposomal and other delivery systems. Cell Mol. Biol. Lett. 14 (2009) 139-152
10. El-Shabouri M.H. Positively charged nanoparticles for improving the oral bioavailability of cyclosporin A. Int. J. Pharm. 249 (2002) 101-108
11. Fahr A. Cyclosporin clinical pharmacokinetics. Clin. Pharmacokinet. 24 (1993) 472-495
12. FDA guidance of industry, Q8 pharmaceutical development, U.S. Department of Health and Human Services, FDA/CDER/CBER, Rockville, MD, USA, May 2006.
13. Hatton J., Rosbolt B., Empey P., Kryscio R., and Young B. Dosing and safety of cyclosporine in patients with severe brain injury. J. Neurosurg. 109 (2008) 699-707
14. Higuchi, T., 1963. Mechanism of sustained-action medication: theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J. Pharm. Sci. 52, 1145-1149. http://www.engineersedge.com/fluid_flow/fluid_data.htm visited on July 22, 2009 http://www.inchem.org/documents/icsc/icsc/eics0027.htm visited on July 22, 2009 http://www.inchem.org/documents/icsc/icsc/eics0058.htm visited on July 22 2009.
15. Italia J.L., Bhatt D.K., Bhardwaj V., Tikoo K., and Kumar M.N. PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune. Neoral. J. Control. Release 119 (2007) 197-206
16. Jalil R., and Nixon J.R. Microencapsulation using poly(l-lactic acid) I: microcapsule properties affected by the preparation technique. J. Microencapsul. 6 (1989) 473-484
17. Jeffery H., Davis S.S., and O'Hagan D.T. The preparation and characterization of poly(lactide-co-glycolide) microparticles. I. Oil-in-water emulsion solvent evaporation. Int. J. Pharm. 77 (1991) 169-175
18. Kawashima Y., Yamamoto H., Takeuchi H., Fujioka S., and Hino T. Pulmonary delivery of insulin with nebulized dl-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. J. Control. Release 62 (1999) 279-287
19. Khan K.A. The concept of dissolution efficiency. J. Pharm. Pharmacol. 27 (1975) 48-49
20. Lechuga-Ballestros D., Abdul-Fattah A., Stevenson C.L., and Bennett D.B. Properties and stability of a liquid crystal form of cyclosporine-the first reported naturally occurring peptide that exists as a thermotropic liquid crystal. J. Pharm. Sci. 92 (2003) 1821-1831
21. Lemley D.E., and Katz P. Therapeutic strategies in autoimmune disease: cyclosporin A as a model agent. In Vivo 2 (1988) 115-118
22. Lindholm A., Henricsson S., Lind M., and Dahlqvist R. Intra-individual variability in the relative systemic availability of cyclosporine after oral dosing. Eur. J. Clin. Pharmacol. 34 (1988) 461-464
23. Matilainen L., Järvinen K., Toropainen T., Näsi E., Auriola S., Järvinen T., and Jarho P. In vitro evaluation of the effect of cyclodextrin complexation on pulmonary deposition of a peptide, cyclosporin A. Int. J. Pharm. 318 (2006) 41-48
24. Matzke G.R., and Luke D.R. Dialysis and renal transplant therapy. In: Herfindal E.T., Gourley D.R., and Hart L.L. (Eds). Clinical Pharmacy and Therapeutics (1988), Williams and Wilkins, Baltimore 229-242
25. Merchant H.A., Shoaib H.M., Tazeen J., and Yousuf R.I. Once-daily tablet formulation and in vitro release evaluation of cefpodoxime using hydroxypropyl methylcellulose: a technical note. AAPS PharmSciTech. 7 (2006) Article 78
26. Miyake K., Hirayama F., and Uekama K. Solubility and mass and nuclear magnetic resonance spectroscopic studies on interaction of cyclosporin A with dimethyl-α- and β-cyclodextrins in aqueous solution. J. Pharm. Sci. 88 (2000) 39-45
27. Motwani S.K., Chopra S., Talegaonkar S., Kohli K., Ahmad F.J., and Khar R.K. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimization and in vitro characterization. Eur. J. Pharm. Biopharm. 68 (2008) 513-525
28. Plackett R.L., and Burman J.P. The design of optimum multifactorial experiments. Biometrika 33 (1946) 305-325
29. Richardson C., and Emery P. Clinical use of cyclosporin in rheumatoid arthritis. Drugs 50 (1995) 26-36
30. Shi K., Cui F., Yamamoto H., and Kawashima Y. Optimized formulation of high-payload PLGA nanoparticles containing insulin-lauryl sulfate complex. Drug Dev. Ind. Pharm. 35 (2009) 177-184
31. Siepmann J., and Peppas N.A. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv. Drug Deliv. Rev. 48 (2001) 139-157
32. Varela M.C., Guzman M., Molpeceres J., del Rosario Aberturas M., Rodriquez-Puyol D., and Rodriquez-Puyol M. Cyclosporine-loaded polycaprolactone nanoparticles: immunosuppression and nephrotoxicity in rats. Eur. J. Pharm. Sci. 12 (2001) 471-478
33. Wang X.Q., Dai J.D., Chen Z., Zhang T., Xia G.M., Nagai T., and Zhang Q. Bioavailability and pharmaceutics of cyclosporine A-loaded pH sensitive nanoparticles for oral administration. J. Control. Release 97 (2004) 421-429
34. Wischkel C., and Schwendeman S.P. Principles of encapsulating hydrophobic drugs in PLA/PLGA. Int. J. Pharm. 364 (2008) 298-327
35. Yadav P.K., and Liu Z. Current strategies for the treatment of ulcerative colitis. Recent Pat. Inflamm. Allergy Drug Discov. 3 (2009) 65-72
36. Yang Q., and Owusu-Ababio G. Biodegradable progesterone microsphere delivery system for osteoporosis therapy. Drug Dev. Ind. Pharm. 26 (2000) 61-70
37. Yang Y.Y., Chung T.S., Bai X.L., and Chan W.K. Effect of preparation condition on morphology and release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion method. Chem. Eng. Sci. 55 (2000) 2223-2236
38. Yang Y.Y., Chung T.S., and Ng N.P. Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. Biomaterial 22 (2001) 231-241
39. Yeung E., and Chaw C.S. Cyclosporin-loaded poly(lactide) microparticles: effect of TPGS. J. Microencapsul. 26 (2009) 9-17